Shots:
- BioMarin has entered into a definitive agreement to acquire Inozyme, strengthening its enzyme therapies portfolio with the addition of INZ-701, an enzyme replacement therapy
- As per the deal, Inozyme’s shareholders will receive $4.00 per share in an all-cash transaction for a total consideration of ~$270M; closing is expected in Q3’25
- INZ-701 (SC) is being evaluated in an ongoing P-III trial for ENPP1 deficiency in children, with data expected in early 2026 & potential approval in 2027, while infant enrollment is ongoing in a pivotal study & a supportive study for adolescents & adults is planned
Ref: BioMarin Pharmaceutical | Image: Inozyme | Press Release
Related News:- QIAGEN to Acquire Genoox for ~$80M
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
